EUVIMEDEUVIMED entdecken
Open Access

PRMT1 mediated asymmetric dimethylation of arginine residue 602 in DDX1 promotes cholangiocarcinoma progression

Wenzheng Liu, Yangwei Liao, Yiyang Kuai, Xin Gao, Xingmin Yan, Jingjing Li, Junsheng Chen, Jukun Su, Jingcong Zhou, Yizhu Kong, Siqin Huang, Zhiwei Zhang und 3 weitere

Clinical and Molecular Hepatology · 2026

DOI: 10.3350/cmh.2025.1252 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Molecular Hepatology, 2026. Verfasst von Wenzheng Liu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hepato-Pancreato-Biliary Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei, P.R…. Hauptthemen laut MEDLINE: Protein-Arginine N-Methyltransferases, Cholangiocarcinoma, Bile Duct Neoplasms, DEAD-box RNA Helicases. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Key Research and Development Program of Hubei Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIMS: Cholangiocarcinoma (CCA) is a primary malignant neoplasm with an extremely poor prognosis. While combined chemoradiotherapy has been demonstrated to delay CCA progression to a certain extent, the absence of specific molecular biomarkers or targets significantly hinders the diagnosis and treatment of CCA. METHODS: Through cross-analysis of proteomics and ADMA modificationomics, we identified DDX1 overexpressed in CCA with elevated R602-ADMA modifications. HPLC-MS/MS identified PRMT1 as the methyltransferase and USP10 as the deubiquitinating enzyme for DDX1. Immunofluorescence and nuclear-cytoplasmic partitioning experiments confirmed DDX1's nuclear localization. GO and KEGG analyses clarify the biological functions of DDX1 in response to hypoxia. RNA-seq transcriptomics analyzed key pathways influenced by DDX1. A hydrodynamic in situ CCA mouse model was established to validate the chemopreventive effects of the PRMT1-specific inhibitor GSK715 on CCA development. RESULTS: DDX1 promotes CCA progression both in vivo and in vitro and can be inhibited by GSK715. Mechanistically, PRMT1 mediates ADMA modification at position R602 of DDX1. This modification promotes DDX1 nuclear localization by recruiting USP10 to deubiquitinate DDX1, while simultaneously inhibiting PRMT1 degradation. DDX1 promotes the transcription of PRMT1 and USP10 by binding to the mRNA 3'UTR region, establishing a positive feedback regulatory pathway. This mechanism promotes the occurrence and development of CCA and can serve as a target for the inhibitor GSK715 to suppress CCA progression. CONCLUSIONS: Our study identified DDX1-R602-ADMA modification as a novel ADMA modification in CCA. It further confirmed its pivotal role in CCA progression. Targeting the USP10-PRMT1-DDX1 axis may represent a significant therapeutic approach for CCA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein-Arginine N-MethyltransferasesCholangiocarcinomaBile Duct NeoplasmsDEAD-box RNA HelicasesArginineRepressor ProteinsHumansAnimalsUbiquitin ThiolesteraseMiceCell Line, TumorMethylationDisease ProgressionUbiquitination

Stichwörter der Autor:innen

Arginine asymmetric dimethylationCholangiocarcinomaDDX1PRMT1Ubiquitination

Substanzen

Protein-Arginine N-MethyltransferasesPRMT1 protein, humanUbiquitin ThiolesteraseDEAD-box RNA HelicasesArginineRepressor ProteinsDDX1 protein, human

Autor:innen und Institutionen

  • Division of Hepato-Pancreato-Biliary Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei, P.R.China.

Förderung

  • National Natural Science Foundation of China
  • Key Research and Development Program of Hubei Province

Zitieren

APA

Liu, W., Liao, Y., Kuai, Y., Gao, X., Yan, X., Li, J., Chen, J., Su, J., Zhou, J., Kong, Y., Huang, S., Zhang, Z., Peng, F., Wang, B., & Chen, Y. (2026). PRMT1 mediated asymmetric dimethylation of arginine residue 602 in DDX1 promotes cholangiocarcinoma progression. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2025.1252

Vancouver

Liu W, Liao Y, Kuai Y, Gao X, Yan X, Li J, et al. PRMT1 mediated asymmetric dimethylation of arginine residue 602 in DDX1 promotes cholangiocarcinoma progression. Clinical and Molecular Hepatology. 2026. doi:10.3350/cmh.2025.1252

BibTeX
@article{Liu2026,
  author = {Liu, Wenzheng and Liao, Yangwei and Kuai, Yiyang and Gao, Xin and Yan, Xingmin and Li, Jingjing and Chen, Junsheng and Su, Jukun and Zhou, Jingcong and Kong, Yizhu and Huang, Siqin and Zhang, Zhiwei and Peng, Feng and Wang, Bing and Chen, Yongjun},
  title = {PRMT1 mediated asymmetric dimethylation of arginine residue 602 in DDX1 promotes cholangiocarcinoma progression},
  journal = {Clinical and Molecular Hepatology},
  year = {2026},
  doi = {10.3350/cmh.2025.1252}
}
Kostenlos starten →